Summary of PHG Q2 2026 Earnings Call

1Key Financial Results and Metrics

Comparable Sales Growth: Increased by 4% in Q2 2026, driven by growth across all segments.

Adjusted EBITA Margin: Rose to 16.4%, benefiting from a tariff refund; underlying margin was 12.2%, reflecting pressure from higher tariffs and cost inflation.

Free Cash Flow: Reported at EUR 222 million, including the tariff refund benefit.

Order Intake: Grew 5% on a rolling 12-month basis, though Q2 order intake declined by 1% due to timing of larger orders moving to Q3.

Net Debt: EUR 5.7 billion with a leverage ratio improved to 1.8x.

2Strategic Updates and Business Highlights

Diagnosis & Treatment (D&T): Continued strong performance in Image Guided Therapy (IGT) with high single-digit growth; however, Precision Diagnosis faced low single-digit decline, particularly affected by weakness in China.

Connected Care: Monitoring segment showed mid-single-digit growth, driven by hospital investments.

Personal Health: Achieved 8% growth, with strong contributions from new product launches in oral care and personal care.

Innovation: Continued focus on AI and new product launches, such as the Spectral CT Verida and helium-free MRI, which are gaining traction.

Strategic Partnerships: Expanded collaborations with health systems and government initiatives to enhance innovation and market reach.

3Forward Guidance and Outlook

Full Year Comparable Sales Growth: Reiterated guidance of 3% to 4.5%, with expectations for Connected Care and Personal Health to grow at the upper end of this range.

Adjusted EBITA Margin: Expected to be between 12.5% and 13% for the full year, with Q3 margins anticipated to be below the prior year due to cost inflation.

Free Cash Flow Guidance: Revised to EUR 1.5 billion to EUR 1.7 billion, including tariff refunds.

4Bad News, Challenges, or Points of Concern

China Market: Continued weakness in health systems due to centralized procurement policies and subdued hospital investments, impacting D&T margins.

Cost Inflation: High single-digit inflation expected for 2026, with ongoing pressures from tariffs and currency effects.

Enterprise Informatics: Experienced mid-single-digit sales decline for two consecutive quarters, attributed to the transition to a SaaS model and longer implementation times for large orders.

Order Intake Timing: Some larger orders shifted to Q3, causing a temporary decline in Q2 order intake.

5Notable Q&A Insights

D&T Margin Performance: Concerns raised about lower-than-expected margins in D&T, attributed to cost inflation, tariffs, and currency effects.

China's Centralized Procurement: Management acknowledged the impact of government policies on pricing and margins, but emphasized the strength of differentiated products in maintaining competitiveness.

Future Order Growth: Management expressed confidence in returning to mid-single-digit order growth in Q3, supported by strong pipelines in North America and Europe.

Visibility on Q4 Performance: Management reassured that Q4 margins would improve significantly, driven by higher volumes and innovation-led gross margin improvements. Overall, Philips demonstrated resilience in a challenging environment with solid growth metrics, though faced with ongoing inflationary pressures and market challenges, particularly in China. The company remains focused on executing its strategic initiatives and maintaining a strong outlook for the remainder of the year.